The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of stage II hypertensive patients (MSSBP ≥ 160 mmHg).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
647
Novartis Pharmaceuticals Corp
East Hanover, New Jersey, United States
Change from baseline in MSSBP at week 4
Change from baseline MSSBP after 2 and 8 weeks of treatment
Change from baseline MSDBP after 2, 4 and 8 weeks of treatment
Proportion of patients reaching overall BP control (MSSBP < 140 mmHg and MSDBP < 90mmHg) after 8 weeks of treatment
Evaluation of safety and tolerability after 8 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.